Home
Development Programs
For Investors
News
About Us
- Our Name & Brandmark
- Team
Contact

Menu

Home
Development Programs
For Investors
News
About Us
- Our Name & Brandmark
- Team
Contact

opioid

Investor Webinar | Emyria validated care model

Jun 09, 2021

Investor Webinar | Emyria validated care model

Search

Search for:

Blogs
General News
In the Media
Information
Investor Updates
Publications

Tag Cloud

anxiety bioavailability blog CBD clinical research dr alistair vickery drug development EMD EMD-RX5 emd-rx7 emyria investor mdma mdma analogue program medicinal cannabis medicinal CBD treatments national institutes for health news NINDS opioid over the counter pain. preclinical psychological conditions psychological distress screening results ultra-pure CBD webinar

Have Questions?

If you have any question, please feel free to get in touch with us.

DEVELOPMENT PROGRAMS

Ultra-Pure CBD Medicines
MDMA-inspired Medicines
Research & Data Programs

Ultra-Pure CBD Medicines
MDMA-inspired Medicines
Research & Data Programs

FOR INVESTORS

Stock Information
ASX Announcements
Presentations & Videos
Reports & Updates
Corporate Governance

Stock Information
ASX Announcements
Presentations & Videos
Reports & Updates
Corporate Governance

RECENT TWEETS

Over 50 patients are currently enrolled in our pivotal Phase 3 Clinical Trial of EMD-RX5, with 83 patients awaiting dosing & another 1700+ successfully pre-screened. The trial is expected to conclude in July 2023. $EMD Full update 📩 https://t.co/WQPXXzZLWn

© 2023 Emyria Limited

Terms | Privacy | Website by Glide

Phone
08 6559 2800

Email
info@emyria.com

Linkedin Twitter Youtube

First Name*
Last Name*
Email*
Post code
What news are you interested in?*
- Clinical news
- Patient news
- Investor news
- Partners news
CAPTCHA
Comments
This field is for validation purposes and should be left unchanged.

Δ

Search for:

Hit enter to search or ESC to close

Home
Development Programs
For Investors
News
About Us
- Our Name & Brandmark
- Team
Contact

Call 08 6559 2800 Contact